Oncternal Therapeutics Statistics
Share Statistics
Oncternal Therapeutics has 2.96M shares outstanding. The number of shares has increased by -94.98% in one year.
| Shares Outstanding | 2.96M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.71M |
| Failed to Deliver (FTD) Shares | 14.33K |
| FTD / Avg. Volume | 10.21% |
Short Selling Information
The latest short interest is 45.35K, so 1.53% of the outstanding shares have been sold short.
| Short Interest | 45.35K |
| Short % of Shares Out | 1.53% |
| Short % of Float | 1.71% |
| Short Ratio (days to cover) | 0.36 |
Valuation Ratios
The PE ratio is -0.8 and the forward PE ratio is -0.12.
| PE Ratio | -0.8 |
| Forward PE | -0.12 |
| PS Ratio | 40.15 |
| Forward PS | 2.6 |
| PB Ratio | 1.05 |
| P/FCF Ratio | -0.98 |
| PEG Ratio | n/a |
Enterprise Valuation
Oncternal Therapeutics Inc. has an Enterprise Value (EV) of 25.14M.
| EV / Earnings | -0.64 |
| EV / Sales | 32.02 |
| EV / EBITDA | 11.25 |
| EV / EBIT | -0.6 |
| EV / FCF | -0.78 |
Financial Position
The company has a current ratio of 6.94, with a Debt / Equity ratio of 0.
| Current Ratio | 6.94 |
| Quick Ratio | 6.94 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.31% and return on capital (ROIC) is -137.35%.
| Return on Equity (ROE) | -1.31% |
| Return on Assets (ROA) | -1.07% |
| Return on Capital (ROIC) | -137.35% |
| Revenue Per Employee | 29.07K |
| Profits Per Employee | -1.46M |
| Employee Count | 27 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -93.85% in the last 52 weeks. The beta is 1.36, so Oncternal Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | -93.85% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 5.83 |
| Relative Strength Index (RSI) | 25.16 |
| Average Volume (20 Days) | 140.32K |
Income Statement
In the last 12 months, Oncternal Therapeutics had revenue of $785.00K and earned -$39.48M in profits. Earnings per share was $-13.43.
| Revenue | 785.00K |
| Gross Profit | -28.97M |
| Operating Income | -41.71M |
| Net Income | -39.48M |
| EBITDA | 2.23M |
| EBIT | -41.71M |
| Earnings Per Share (EPS) | -13.43 |
Balance Sheet
The company has $6.70M in cash and $318.00K in debt, giving a net cash position of $6.38M.
| Cash & Cash Equivalents | 6.70M |
| Total Debt | 318.00K |
| Net Cash | 6.38M |
| Retained Earnings | -197.78M |
| Total Assets | 15.60M |
| Working Capital | 8.99M |
Cash Flow
In the last 12 months, operating cash flow was -$32.16M and capital expenditures $0, giving a free cash flow of -$32.16M.
| Operating Cash Flow | -32.16M |
| Capital Expenditures | 0 |
| Free Cash Flow | -32.16M |
| FCF Per Share | -10.94 |
Margins
Gross margin is -3.69K%, with operating and profit margins of -5.31K% and -5.03K%.
| Gross Margin | -3.69K% |
| Operating Margin | -5.31K% |
| Pretax Margin | -5.03K% |
| Profit Margin | -5.03K% |
| EBITDA Margin | 284.71% |
| EBIT Margin | -5.31K% |
| FCF Margin | -4.10K% |
Dividends & Yields
ONCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2533.96% |
| FCF Yield | -2063.72% |
Analyst Forecast
The average price target for ONCT is $10, which is 1786.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $10 |
| Price Target Difference | 1786.8% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 8, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Jan 8, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -30.51 |
| Piotroski F-Score | 2 |